|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.60 EUR | +0.25% |
|
+0.34% | +15.56% |
Summary: bioMérieux
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to MSCI.
Highlights: bioMérieux
- The company is in a robust financial situation considering its net cash and margin position.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses: bioMérieux
- The company benefits from high valuations in earnings multiples.
- The company's enterprise value to sales, at 3.24 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings Chart: bioMérieux
Source: Surperformance
ESG chart: bioMérieux
Source: MSCI
| Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
|---|---|---|---|---|---|
| 16.45B | |||||
| 6.05B | |||||
| 5.71B | |||||
| - | 5.63B | ||||
| - | 3.02B | ||||
| 2.08B | |||||
| Average | 6.49B | ||||
| Weighted average by Cap. |
Investor (Composite)
Trader (Composite)
ESG MSCI
AA
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)
Valuation
P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIM Stock
- Ratings bioMérieux
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition